Nebulized 5% Hypertonic Saline for the Treatment of Bronchiolitis

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators reasoned that a hypertonic saline concentration higher than 3% could be safe and more efficacious in the treatment of bronchiolitis, alleviating severe symptoms and preventing the need for hospitalization in some instances.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamad Medical Corporation
• Treatments: Epinephrine; Epinephryl borate; Racepinephrine

Criteria

Inclusion Criteria:

• Infants aged ≤ 18 months presenting to the unit for the treatment of moderate-severe viral bronchiolitis were eligible for the study.

• Moderate-severe bronchiolitis required having a prodromal history consistent with viral upper respiratory tract infection followed by wheezing and/or crackles on auscultation and a Wang bronchiolitis severity score of ≥ 4 on presentation.

Exclusion Criteria:

Patients were excluded from the study if they had one or more of the following characteristics:

• Born preterm ≤ 34 weeks gestation,

• Previous history of wheezing,

• Steroid use within 48 hours of presentation,

• Obtundation and progressive respiratory failure requiring ICU admission,

• History of apnea with in 24 hours before presentation,

• Oxygen saturation ≤ 85% on room air at the time of recruitment,

• History of a diagnosis of chronic lung disease,

• Congenital heart disease, or

• Immunodeficiency.